|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current | ||||||||
| Cash and cash equivalents | ||||||||
| Short-term investments (Note 2) | ||||||||
| Accounts receivable (Notes 3) | ||||||||
| Prepaids and other current assets (Note 4) | ||||||||
| Total current assets | ||||||||
| Long term deposit (Note 15) | ||||||||
| Property and equipment (Note 6) | ||||||||
| Patents and licenses (Note 7) | ||||||||
| Right of use asset (Note 8) | ||||||||
| Total assets | ||||||||
| Liabilities | ||||||||
| Current | ||||||||
| Accounts payable and accrued liabilities (Note 9) | ||||||||
| Convertible debt (Note 5) | ||||||||
| Lease liability (Note 8) | ||||||||
| Derivative warrant liability (Note 10 and 11(b)) | ||||||||
| Contract liabilities (Note 3) | ||||||||
| Covid-19 government support loans (Note 23) | ||||||||
| Total current liabilities | ||||||||
| Non-current lease liability (Note 8) | ||||||||
| Derivative warrant liability (Note 10 and 11(b)) | ||||||||
| Total liabilities | ||||||||
| Shareholders’ Equity | ||||||||
| Share capital (Note 11(b)) | ||||||||
| Warrants and compensation options (Note 12) | ||||||||
| Contributed surplus (Note 13) | ||||||||
| Accumulated other comprehensive loss | ||||||||
| Deficit | ||||||||
| Total shareholders’ equity | ||||||||
| Total shareholders’ equity and liabilities | ||||||||
Loading...
